Digital tools are moving from experimental pilots towards integration in everyday care delivery. Remote patient monitoring, digital therapeutics and hybrid care models increasingly appear within treatment pathways rather than alongside them. Early digital therapeutics demonstrated measurable outcomes in controlled settings, while remote monitoring showed that care could extend beyond traditional facilities. Despite these advances, adoption has remained uneven. Regulatory clearance has not guaranteed routine use, and reimbursement has not ensured sustained implementation. At the same time, healthcare systems face increasing pressure from ageing populations, rising chronic disease and workforce shortages linked to clinician attrition and burnout. Non-communicable diseases account for approximately 75% of global deaths, diabetes exceeds $1 trillion (≈€920 billion) in annual global health expenditure and mental health conditions remain a leading cause of long-term disability worldwide. Under these conditions, digital health must operate inside existing care structures rather than as an additional layer.
From Add-On to Embedded Care
Many early digital therapeutics entered clinical environments as standalone interventions that required new prescribing patterns, separate dashboards and data streams outside established electronic health record workflows. In already strained clinical settings, even clinically promising tools introduced additional complexity. Patients also encountered barriers because sustained engagement depended on digital literacy and confidence in how personal data were managed. Concerns around privacy, interoperability and device reliability slowed adoption. Limited uptake reflected not only the maturity of digital tools but also the degree to which they aligned with existing care delivery structures.
That alignment is gradually evolving. In cardiometabolic disease management, digital therapeutics are increasingly incorporated into longitudinal care rather than positioned as optional additions. Digital interventions in hypertension support health literacy and encourage a more active role for patients in disease management. When combined with home monitoring, these tools support sustained blood pressure control and facilitate ongoing treatment optimisation within routine care pathways.
A similar shift appears in diabetes management. Programmes combining continuous monitoring with behavioural support address the long-term nature of the condition. Real-time visibility into physiological data can reduce treatment burden while improving glycaemic control. Integration into established care pathways also expands access to specialised support for populations in rural or underserved settings.
Must Read:Cloud–Edge Monitoring Across Digital Health Domains
Mental health illustrates both progress and limitations. FDA-cleared digital therapeutics including EndeavorRx ADHD and reSET for addiction established regulatory precedents. However, routine adoption has remained limited, partly because of reimbursement uncertainty and unclear implementation pathways. Many digital mental health models function as adjuncts to conventional therapy and are designed to operate without continuous clinician oversight, extending care beyond traditional clinical capacity.
Frameworks and Funding Are Taking Shape
As digital care becomes more embedded in clinical practice, institutional frameworks are evolving to accommodate software-enabled interventions. Updates to US Food and Drug Administration guidance on digital health, including revisions concerning Clinical Decision Support software and General Wellness products, clarify how different software functions fall within regulatory oversight. These updates distinguish which applications qualify as regulated medical devices and which remain outside that scope.
Additional frameworks are shaping the regulatory landscape. The FDA’s Prescription Drug Use-Related Software framework and Europe’s Health Data Space Regulation address how digital tools and the health data they generate interact with regulatory systems. PDURS outlines how software that demonstrates clinical benefit can be incorporated into a drug label, establishing a pathway for combined drug–software therapeutic approaches. These frameworks contribute to clearer regulatory boundaries for digital interventions within broader healthcare systems.
Reimbursement pathways are also developing. Germany’s Digitale-Versorgung-Gesetz, or DiGA, provides a structured mechanism for evaluating, prescribing and reimbursing digital health applications within a statutory healthcare system under defined evidentiary standards. In the United States, expanded billing codes for remote patient monitoring and related services reflect care models that extend across connected devices, patient homes and virtual interactions. More than 300 hospitals in the United States are authorised to deliver hospital-at-home services, reflecting the broader expansion of distributed care models.
Remote patient monitoring is increasingly used within discharge planning and chronic disease management programmes. Evidence from meta-analytic analysis indicates that remote monitoring significantly reduces heart failure-related hospitalisations compared with standard care while improving health-related quality of life. As multimorbidity rises, these approaches support earlier detection of clinical deterioration and reduce unplanned hospital admissions.
Digital Tools Are Reshaping Treatment Models
As digital health tools move from isolated deployments to routine use, their influence extends beyond service delivery into therapeutic strategies. Pharmaceutical engagement in digital health has historically focused on adherence programmes, patient support services, connected drug-device ecosystems, digital biomarkers and decentralised clinical trials. These initiatives primarily supported medication use or data generation rather than influencing how therapies function in clinical practice.
That distinction is becoming less clear. As remote monitoring and software-based interventions become embedded within care models, digital components increasingly shape real-world therapeutic performance. In conditions where adherence, behavioural reinforcement, symptom tracking or early detection influence outcomes, software interventions can contribute alongside pharmacological treatment.
Examples of this shift appear across therapeutic areas. Software-based therapies for major depressive disorder illustrate attempts to combine digital interventions with established treatment approaches. In oncology care, digital companions support symptom monitoring between clinical visits. Connected technologies such as smart insulin pens and sensor-enabled inhalers integrate monitoring directly into daily therapeutic use.
These developments suggest a broader transformation. Digital therapeutics and remote monitoring gain traction when they operate as extensions of care pathways rather than as independent products. As digital tools increasingly contribute to evidence generation and patient-facing care delivery, the strategic focus shifts from whether organisations should adopt digital health to how therapies function within healthcare systems that are themselves becoming digitally enabled.
Digital health is entering a phase of operational integration. Clinical validation has advanced across several therapeutic areas, regulatory frameworks are evolving and reimbursement models are gradually adapting. The remaining challenge concerns consistent implementation within everyday care environments. Healthcare systems face growing demand and require models that extend care without increasing fragmentation. Digital interventions demonstrate value when they align with existing workflows, support structured care pathways and complement established therapies. Their long-term role will depend on the ability to function reliably within healthcare systems while generating measurable clinical and operational value over time.
Source: HLTH
Image Credit: iStock
